Human Papillomavirus

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

2100%

+ 26 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

8 programs

V503Phase 3

GardasilPhase 2

Gardasil vaccineN/AVaccine

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A

+3 more programs

Sharp TherapeuticsPA - Pittsburgh

8 programs

V503Phase 3

GardasilPhase 2

Gardasil vaccineN/AVaccine

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A

+3 more programs

GenexineKorea - Seoul

1 program

GX-I7Phase 11 trial

Active Trials

NCT03144934Completed32Est. Mar 2018

Merck & Co.RAHWAY, NJ

5 programs

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A1 trial

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A1 trial

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)N/A1 trial

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)N/A1 trial

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College N/A1 trial

Active Trials

NCT01422356Completed200Est. Sep 2013

NCT01159834Completed1,574Est. Dec 2011

NCT03000933Completed200Est. Dec 2019

+2 more trials

AbbottABBOTT PARK, IL

1 program

Alinity m HR HPVN/A1 trial

Active Trials

NCT04746872Completed14,935Est. Nov 2022

Alliance PharmaceuticalsUK - Wiltshire

1 program

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)N/A

Angeles TherapeuticsCA - Los Angeles

1 program

Natural History of HPV From Infection to Neoplasia in Adolescents and Young WomenN/A1 trial

Active Trials

NCT01366742Completed900Est. May 2016

Allergy TherapeuticsUK - West Sussex

1 program

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)N/A1 trial

Active Trials

NCT05026138Recruiting850Est. Mar 2047

PfizerNEW YORK, NY

1 program

ParticipatoryN/A

Human BioSciencesWV - Martinsburg

1 program

ParticipatoryN/A1 trial

Active Trials

NCT02377843Completed30Est. Mar 2016

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

GenexineGX-I7

Allergy TherapeuticsNatural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

AbbottAlinity m HR HPV

Merck & Co.Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

Human BioSciencesParticipatory

Merck & Co.Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Merck & Co.KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

Merck & Co.Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Merck & Co.Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Angeles TherapeuticsNatural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Clinical Trials (10)

Total enrollment: 20,217 patients across 10 trials

NCT03144934 GenexineGX-I7

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Start: Feb 2017Est. completion: Mar 201832 patients

Phase 1Completed

NCT05026138 Allergy TherapeuticsNatural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

Start: Nov 2021Est. completion: Mar 2047850 patients

N/ARecruiting

NCT04746872 AbbottAlinity m HR HPV

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

Start: Feb 2021Est. completion: Nov 202214,935 patients

N/ACompleted

NCT03000933 Merck & Co.Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

Start: Jan 2017Est. completion: Dec 2019200 patients

N/ACompleted

NCT02377843 Human BioSciencesParticipatory

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

Start: Mar 2015Est. completion: Mar 201630 patients

N/ACompleted

NCT01289873 Merck & Co.Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women

Start: May 2011Est. completion: Sep 20121,036 patients

N/ACompleted

NCT01314404 Merck & Co.KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

Start: Mar 2011Est. completion: Sep 2012460 patients

N/AUnknown

NCT01159834 Merck & Co.Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Start: Sep 2010Est. completion: Dec 20111,574 patients

N/ACompleted

NCT01422356 Merck & Co.Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Start: Sep 2010Est. completion: Sep 2013200 patients

N/ACompleted

NCT01366742 Angeles TherapeuticsNatural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Start: Dec 1987Est. completion: May 2016900 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 20,217 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.